$120.61
-0.23(-0.19%)
Mkt Cap $298.2B
$73.47
$123.93
52-Week Range
At A Glance
1
Merck & Co., Inc.
2
Revenue is primarily driven by Keytruda (45.6%) and Gardasil Gardasil9 (12%).
3
Most recently: . Results of Operations and Financial Condition . The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02. Incor (2026-02-03).
$298.2B
Market Cap
$64.6B
Revenue
$18.1B
Net Income
Employees73,000
Fundamentals
How The Business Makes Money
Revenue by Segment
Keytruda45.6%($172.3B)
Gardasil Gardasil912%($45.4B)
Livestock5.7%($21.4B)
Other Pharmaceutical4.3%($16.1B)
Pro Quad MMRII Varivax3.9%($14.6B)
Companion Animals3.8%($14.3B)
Bridion2.9%($10.9B)
Januvia2.7%($10.3B)
Lagevrio2.2%($8.3B)
Alliancerevenue Lynparza2.1%($7.9B)
Janumet1.6%($6.1B)
Lenvima1.6%($6.0B)
Prevymis1.3%($4.7B)
Vaxneuvance1.2%($4.6B)
Rotateq1.1%($4.3B)
Winrevair1%($3.7B)
Welireg0.8%($2.9B)
Adempas0.7%($2.6B)
Simponi0.7%($2.5B)
Alliance Revenue Adempas Verquvo0.7%($2.5B)
Isentress Isentress HD0.6%($2.4B)
Alliance Revenue Reblozyl0.6%($2.2B)
Dificid0.5%($1.8B)
Capvaxive0.5%($1.7B)
Pneumovax230.4%($1.7B)
Zerbaxa0.4%($1.6B)
Delstrigo0.4%($1.5B)
Belsomra0.3%($1.3B)
Pifeltro0.3%($951M)
Remicade0.2%($602M)
Ohtuvayre0.1%($356M)
Verquvo0%($121M)
Keytruda Qlex0%($80M)
Revenue by Geography
US46%($388.2B)
Non Us43.1%($364.3B)
EMEA5%($41.9B)
CN1.7%($14.2B)
Latin America1.2%($10.0B)
Asia Pacific1.1%($9.3B)
JP1.1%($9.2B)
Other Countries0.9%($7.5B)
Activity
Analyst View
Company Profile
CIK0000310158
ISINUS58933Y1055
CUSIP58933Y105
Phone908 740 4000
Address2000 Galloping Hill Road, Rahway, NJ, 07033, US
SEC EDGAR